U.S. STOCKS ON THE MOVE-McDonald, Coherus BioSciences, Miromatrix,

Miromatrix Medical

30/10/2023 12:15

* 
      Eikon search string for individual stock moves:  STXBZ 
    

        * 
      The Day Ahead newsletter: https://refini.tv/3LI4BU7
    

        * 
      The Morning News Call newsletter: https://refini.tv/3dKUyB8
    

  
Futures for Wall Street's main stock indexes rose on Monday ahead of a busy week
of earnings and interest rate decisions from major central banks including the
Federal Reserve, while investors shrugged off concerns about the Middle East
conflict.  .N 
    
    At 7:35 ET, Dow e-minis  1YMc1  were up 0.62% at 32,704. S&P 500 e-minis
 ESc1  were up 0.64% at 4,164.25, while Nasdaq 100 e-minis  NQc1  were up 0.74%
at 14,370.5.
 
 The top three NYSE percentage gainers premarket  .PRPG.NQ :
 ** The Aarns Co Ord  AAN , up 22.2%
 ** Fsclnt Hld A Ord  NOTE.K , up 13.6%
 ** Spirit Relty Ctl  SRC , up 12.7%
 
 The top three NYSE percentage losers premarket  .PRPL.NQ :
 ** Revvity Inc Ord  RVTY.K , down 8.3%
 ** Mntr Envrmtl Ord  MEG , down 5.7%
 ** Usd Partners Lp  USDP.K , down 5.6%
 
 The top three Nasdaq percentage gainers premarket  .PRPG.O :
 ** Miromatrix Medical Inc  MIRO.O , up 219.2%
 ** Baiyu Holdings Inc  BYU.O , up 67.9%
 ** Conduit Pharmaceuticals Inc  CDT.O , up 65.2%
 
 The top three Nasdaq percentage losers premarket  .PRPL.O :
 ** MultiMetaVerse Holdings Ltd  MMVWW.O , down 49.9%
 ** EUDA Health Holdings Ltd  EUDAW.O , down 45.3%
 ** Semantix Inc  STIXW.O , down 25.7%
 
 
 ** McDonald's Corp  MCD.N : up 3.0% premarket
 BUZZ - Rises after Q3 results beat expectations  urn:newsml:reuters.com:*:nL4N3C02G5 

 ** Coherus BioSciences Inc  CHRS.O : up 22.0% premarket
 BUZZ - Jumps after FDA approval of cancer therapy  urn:newsml:reuters.com:*:nL4N3C02LH 
    
 ** Miromatrix Medical Inc  MIRO.O : up 219.2% premarket
 BUZZ - Rises on buyout by United Therapeutics  urn:newsml:reuters.com:*:nL4N3C02NX
 

 (Reporting by Rajarshi Roy and Aatreyee Dasgupta)
 ((Rajarshi.Roy@thomsonreugters.com
Aatreyee.Dasgupta@thomsonreuters.com))